|Bid||47.11 x 1800|
|Ask||47.11 x 900|
|Day's range||46.75 - 47.32|
|52-week range||37.48 - 52.19|
|Beta (3Y monthly)||0.76|
|PE ratio (TTM)||N/A|
|Earnings date||28 Jan 2020 - 3 Feb 2020|
|Forward dividend & yield||N/A (N/A)|
|1y target est||53.20|
This study result is expected to be a major stride forward in Hologic's (HOLX) commitment toward strengthening its Diagnostic Solutions business.
Hologic (HOLX) delivered earnings and revenue surprises of 0.00% and 2.67%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Stock pickers are generally looking for stocks that will outperform the broader market. And while active stock picking...
Developments in Breast Health and Molecular Diagnostics businesses are likely to have aided Hologic's (HOLX) performance in fourth-quarter fiscal 2019.
Hologic (HOLX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AIX-EN-PROVENCE, France, Oct. 08, 2019 (GLOBE NEWSWIRE) -- SuperSonic Imagine (Euronext: SSI, FR0010526814), a company specialising in medical ultrasound imaging, is expanding its product range and will for the first time present a suite of new ultrasound markers1 alongside its new ultrasound platform, Aixplorer MACH® 20, at the JFR congress. “We have a lot of exciting news for the 2019 edition of the JFR. We are entering the Hologic organization to start a new page in the history of SuperSonic Imagine that will enable us to accelerate our development.
DexCom (DXCM) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Hologic's (HOLX) strong top-line growth in Q3 is led by a solid year-over-year rise in core businesses like Breast Health and Molecular Diagnostics.
Higher revenues and solid segmental performance margins benefit Merit Medical's (MMSI) Q2 earnings. However, contraction in both gross and operating margins remains a concern.
ResMed (RMD) achieves double-digit global revenue growth in the fourth quarter, led by strong sales at Software-as-a-Service businesses as well as of new mask products and devices.
While rising acquisitions and a favorable mix contribute to LabCorp's (LH) Diagnostics business, the disposition of certain businesses and the implementation of PAMA dented the company's growth in Q2.